Stem Cell Clinic

EVOTEC SE REPORTS FIRST HALF-YEAR 2020 RESULTS AND CORPORATE UPDATES (1) – PharmiWeb.com

By Induced Pluripotent Stem Cells

DGAP-News: Evotec SE / Key word(s): Half Year Results 12.08.2020 / 07:37 The issuer is solely responsible for the content of this announcement.

Hamburg, Germany, 12 August 2020: Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809) today announced its financial results for the first half-year of 2020.

OVERALL POSITIVE FINANCIAL PERFORMANCE REFLECTING GROWTH ACROSS ALL BUSINESS LINES

CONVINCING OPERATIONAL PROGRESS

INCREASING EXPANSION OF INFRASTRUCTURE IN MULTIMODALITY

CORPORATE

GUIDANCE FOR FULL-YEAR 2020 CONFIRMED WITH REGARD TO REVENUES AND ADJUSTED EBITDA, HIGHER INVESTMENTS IN R&D PLANNED

STRONG FINANCIAL POSITION Key figures of consolidated income statement & segment information> Evotec SE & subsidiaries - First six months of 2020

In T

1) Thereof unpartnered R&D expenses of 21.6 m in H1 2020 (H1 2019: 18.7 m) 2) Before contingent considerations, income from bargain purchase and excluding impairments on goodwill, other intangible and tangible assets as well as the total non-operating result; adjusted for positive exchange rate effects in the amount of 1.7 m, EBITDA amounts to 45.6 m 3) Not allocated to segments: Revenues from recharges according IFRS 15

In the first six months of 2020 Evotec continued on its growth path: Group revenues from contracts with customers increased by 12% to 231.0 m (H1 2019: 207.1 m) due to a positive performance across all business lines, for the first time added revenues from Just - Evotec Biologics ( 16.3 m) and despite the anticipated loss of payments of Sanofi for the Toulouse site ( 7.5 m) from April 2020. Also, favourable exchange rate effects had a positive impact of 2.4 m.

Thereof, base revenues accounted for 223.2 m, an increase of 19% over the same period of the previous year (H1 2019: 188.0 m), while revenues from upfront, milestone and licence payments decreased to 7.8 m (H1 2019: 19.1 m).

Due to the significant lower upfront, milestone and license payments as well as the anticipated expiring payments from Sanofi for the Toulouse site from April 2020 onwards, gross margin decreased to 23.0% (H1 2019: 30.8%).

In the first half-year of 2020, Evotec continued to strongly invest into its unpartnered R&D. Thus, the expenses for unpartnered R&D increased to 21.6 m (H1 2019: 18.7 m), mainly due to intensified research investments into oncology and platforms such as PanOmics and cell therapy. The lower partnered R&D expenses of 8.2 m (H1 2019: 10.6 m) were primarily related to the infectious disease portfolio. Whereas costs of the partnership with Sanofi in this area are predominantly reported as R&D expenses the full reimbursement by Sanofi is recognised under other operating income. Total R&D expenses of 29.8 m nearly remained stable compared to 2019 (H1 2019: 29.3 m).

The Group's selling, general and administrative ("SG&A") expenses for the first half-year of 2020 increased by 22% to 36.5 m (H1 2019: 29.9 m), which mainly resulted from the overall staff increase and the related costs as well as from transaction and integration cost from equity engagements, the consolidation of Just - Evotec Biologics and the founding of Evotec GT.

Other operating result in the first six months of 2020 amounted to 32.2 m (H1 2019: 31.3 m) and was mainly influenced by R&D tax credits as well as recharges of Sanofi for ID Lyon. Due to a change in the tax regulations in Italian legislation, total R&D tax credits grew less as expected compared to prior period.

The operating income decreased to 18.9 m (H1 2019: 24.0 m), mainly due to the significantly lower upfront, milestone and licence revenues. Most of the half-year milestones are expected to be only slightly delayed, but not lost.

The lower upfront, milestone and licence revenues also affected the adjusted Group EBITDA which decreased by 19% to 47.3 m (H1 2019: 58.2 m). Favourable exchange rate developments had a positive impact of approx. 1.7 m on the adjusted Group EBITDA.

The net result in the first half-year of 2020 amounted to 7.3 m (H1 2019: 10.7 m).

Evotec's liquidity position in the first six months of 2020 continued to remain robust amounting to 275.7 m (31 December 2019: 320.0 m). The cash-outflow resulted mainly from the high investments in capex and equity investments.

CONVINCING OPERATIONAL PERFORMANCE IN BOTH BUSINESS SEGMENTS

In the first half of 2020, the EVT Execute segment continued its strong progress of the previous quarters.

Evotec signed multiple new drug discovery and development agreements, e.g. with Boston Pharmaceuticals and Ildong, as well as multiple undisclosed partners and extended or expanded existing long-term agreements (e.g. with Amgen, Takeda). Evotec's wholly-owned US subsidiary Cyprotex was again selected by the US Environmental Protection Agency (EPA) as its preferred service partner for the next five years. The contract is worth up to $ 13 m.

Evotec's fully-owned subsidiary Just - Evotec Biologics had a successful start with the J.POD(R) construction, progressing well, and its first J.POD(R) collaboration with MSD for the development of innovative technologies for the production of biologics of the highest quality. Further multiple new agreements were concluded (e.g. with ABL, Ology). After period-end, Just - Evotec Biologics entered into a partnership with the U.S. Department of Defense to develop and manufacture monoclonal antibodies (mAbs) for treatment and/or prevention of COVID-19. The contract with the DOD values up to $ 18.2 m.

Also, the Evotec Development Business showed very good performance and started strategic initiatives in the first half-year 2020, despite the extraordinary difficult circumstances especially at the Evotec site in Verona. In June 2020, Evotec's long-term partner Zogenix received its marketing approval from FDA for the company's drug FINTEPLA(R) for Dravet & LGS syndromes, securing 7-year orphan drug exclusivity for commercial exploitation in the US. Evotec will continue to be the commercial manufacturing partner of Zogenix.

In its second segment, EVT Innovate, Evotec was also very successful within the first half-year 2020.

Evotec expanded its leading position in iPSC (Induced pluripotent stem cells). After having regained the global development and commercialisation rights of the iPSC-based diabetes cell therapy programme from Sanofi, Evotec intends to move this programme forward within its QRbeta initiative. Multiple other unpartnered iPSC based initiatives showed very good progress in the first half-year 2020 (e.g. Retinal Diseases).

Evotec's long-term partner, Bayer AG, continues to advance its P2X3 antagonist BAY1817080, an asset originating from Evotec. The Phase IIa-PoC study had a positive outcome in patients with refractory chronic cough. Preparations for a Phase-IIb study in patients with refractory chronic cough are ongoing, as are preparations for further studies in additional indications.

Together with Samsara, Biocapital and KCK Evotec initiated "Autobahn Labs", a novel virtual early stage drug discovery incubator (BRIDGE) to design and execute an accelerated path to deliver transformational new therapies. Autobahn Labs already entered into a first-of-a-kind strategic collaboration with UCLA Technology Development Group to identify and advance the most promising areas of research.

Over the first half of 2020, Evotec continued to expand its strategy of generating upside through equity investments, e.g. in leon-nanodrugs, QUANTRO Therapeutics and Exscientia. Other equity participations were made as follow-on investments (e.g. Carrick) or small seed commitments (e.g. Cajal Neuroscience).

IMPORTANT STRATEGIC BUSINESS EXPANSION INTO NEW MODALITIES AND MARKETS

A very important step towards Evotec's long-term vision of becoming a fully modality-agnostic drug discovery and development partnership company was the establishment of the new site Evotec GT in Austria, dedicated to research and development of gene therapy-based projects. In April, Evotec GT signed a long-term research alliance with Takeda covering selected Takeda gene therapy projects for core therapeutic areas like oncology, rare diseases, neuroscience and gastroenterology.

In June 2020, Evotec signed a strategic partnership with Secarna Pharmaceuticals in the field of Antisense Therapy and already initiated a first project with the aim to establish a pipeline of co-owned antisense oligonucleotide therapies.

Already in the first quarter of 2020, Evotec entered into the field of formulation nanotechnology by signing a strategic partnership with the Munich-based company leon-nanodrugs.

CORPORATE Evotec's shareholders at the virtual Annual General Meeting 2020 approved all proposals the Company's Management put to vote with the required majority. The shareholders elected a new Supervisory Board member: Mr Kasim Kutay, CEO of Novo Holdings A/S, succeeds Dr Michael Shalmi, who resigned from the Board.

In May, Kara Carter, Executive Vice President Infectious Disease of Evotec, was appointed as President of the International Society of the Antiviral Research (ISAR).

Shortly after period-end, on 01 July 2020 Evotec acquired the "Biopark By Sanofi SAS" in Toulouse including all land and buildings of the Sanofi site. The acquisition will allow Evotec to significantly expand its existing capacities at its Toulouse site and to secure further, long-term growth of its Toulouse-based operations. The site will be rebranded into "Campus Curie Toulouse".

FINANCIAL GUIDANCE 2020

At present, the management of Evotec confirms the financial guidance published in the 2019 Annual Report on 26 March 2020 and confirmed in the Q1 Quarterly Statement on 14 May 2020 with regard to revenues and adjusted EBITDA.

Due to additional very promising investments in innovative technology platforms and development candidates in EVT Innovate, Evotec plans to invest even more in research and development. For this reason, the forecast for "unpartnered R&D" has been raised from previously approx. 40 m to now approx. 45 m.

1) EBITDA is defined as earnings before interest, taxes, depreciation, and amortisation of intangibles. Adjusted EBITDA excludes contingent considerations, income from bargain purchase and impairments on goodwill, other intangible and tangible assets as well as the total non-operating result 2) Projections are based on constant 2019 exchange rates 3) Despite increased R&D investments, the expected loss of the Sanofi payments for the Toulouse site after Q1 2020 and significantly ramping up the Just - Evotec Biologics business by investing in and building highly innovative J.POD(R) capacities in the USA

Webcast/Conference Call

The Company is going to hold a conference call to discuss the results as well as to provide an update on its performance. Furthermore, the Management Board will present an outlook for the fiscal year 2020. The conference call will be held in English.

Conference call details Date: Wednesday, 12 August 2020 Time: 02.00 pm CEST (08.00 am EDT, 01.00 pm BST)

From Germany: +49 69 201 744 220 From France: +33 170 709 502 From Italy: +39 02 3600 6663 From the UK: +44 20 3009 2470 From the USA: +1 877 423 0830 Access Code: 17056811#

A simultaneous slide presentation for participants dialling in via phone is available at https://webcasts.eqs.com/evotec20200812/no-audio

Webcast details To join the audio webcast and to access the presentation slides you will find a link on our home page http://www.evotec.com shortly before the event.

A replay of the conference call will be available for seven days after the conference and can be accessed in Europe by dialling +49 69 20 17 44 222 (Germany) or +44 20 3364 5150 (UK) and in the USA by dialling +1 844 307 9362. The access code is 315597273#. The on-demand version of the webcast will be available on our website: https://www.evotec.com/financial-reports.

NOTE Just - Evotec Biologics (former Just.Bio) was acquired effective July 02, 2019 and was fully consolidated in the Group numbers from the respective date onwards. Furthermore, effective 01 April 2020, Evotec GT started its operations. Hence, numbers for the first half-year 2019 and 2020 are not fully comparable.

ABOUT EVOTEC SE Evotec is a drug discovery alliance and development partnership company focused on rapidly progressing innovative product approaches with leading pharmaceutical and biotechnology companies, academics, patient advocacy groups and venture capitalists. We operate worldwide and our more than 3,000 employees provide the highest quality stand-alone and integrated drug discovery and development solutions. We cover all activities from target-to-clinic to meet the industry's need for innovation and efficiency in drug discovery and development (EVT Execute). The Company has established a unique position by assembling top-class scientific experts and integrating state-of-the-art technologies as well as substantial experience and expertise in key therapeutic areas including neuronal diseases, diabetes and complications of diabetes, pain and inflammation, oncology, infectious diseases, respiratory diseases, fibrosis, rare diseases and women's health. On this basis, Evotec has built a broad and deep pipeline of approx. 100 co-owned product opportunities at clinical, pre-clinical and discovery stages (EVT Innovate). Evotec has established multiple long-term alliances with partners including Bayer, Boehringer Ingelheim, Bristol-Myers Squibb, CHDI, Novartis, Novo Nordisk, Pfizer, Sanofi, Takeda, UCB and others. For additional information please go to http://www.evotec.com and follow us on Twitter @Evotec.

FORWARD LOOKING STATEMENTS Information set forth in this press release contains forward-looking statements, which involve a number of risks and uncertainties. The forward-looking statements contained herein represent the judgement of Evotec as of the date of this press release. Such forward-looking statements are neither promises nor guarantees, but are subject to a variety of risks and uncertainties, many of which are beyond our control, and which could cause actual results to differ materially from those contemplated in these forward-looking statements. We expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any such statements to reflect any change in our expectations or any change in events, conditions or circumstances on which any such statement is based.

Contact Evotec SE: Gabriele Hansen, SVP Head of Global Communications & Marketing, Phone: +49.(0)40.56081-255, gabriele.hansen@evotec.com

12.08.2020 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG. The issuer is solely responsible for the content of this announcement.

The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Archive at http://www.dgap.de

See the article here:
EVOTEC SE REPORTS FIRST HALF-YEAR 2020 RESULTS AND CORPORATE UPDATES (1) - PharmiWeb.com

Cytovia Therapeutics Licenses Productivity-Boosting Manufacturing Technology for Its NK Engager Multifunctional Antibodies From ProteoNic -…

By Induced Pluripotent Stem Cells

August 12, 2020 09:04 ET | Source: Cytovia Therapeutics

NEW YORK and LEIDEN, the Netherlands, Aug. 12, 2020 (GLOBE NEWSWIRE) -- Cytovia Therapeutics, Inc (Cytovia), an emerging biopharmaceutical company developing CAR NK cell therapy and NK engager antibodies for cancer, announced today that it has licensed from ProteoNic BV its 2G UNic technology for boosting recombinant protein production, allowing for cost-effective manufacturing at large scale. Under the agreement, Cytovia gains non-exclusive, worldwide commercial rights for application of the technology to the development of a number of its proprietary NK Engager multifunctional antibodies.

ProteoNics mammalian protein expression technology is designed to improve recombinant protein production levels across a range of host cells, selection systems, and protein targets. This is achieved via the combined effect of novel genetic elements, which synergistically exert a positive effect on recombinant protein production levels. ProteoNics 2G UNic can be combined with other expression-enhancing technologies to improve their performance even further.

Cytovias multifunctional antibody technology was originally developed by the companys scientific co-founder, Dr. Kadouche, and has been validated in multiple constructs and pre-clinical models (Kadouche et al. J.Immunology). Cytovia has also licensed NKp46 antibodies from Hebrew University of Jerusalem. NKp46 activation of Natural Killer cells has shown reduction in tumor growth, metastasis prevention, and reshaping of the tumor micro-environment (Mandelboim et al. Immunity 2018). Cytovia is developing multi-functional antibodies directed at both NKp46 and Tumor Antigens in hematological and solid tumors.

Wei Li, PhD, Chief Scientific Officer of Cytovia, commented: ProteoNics validated expression platform technology improves cell line productivity, especially for complex bio-molecules, and supports the optimized GMP manufacturing of our NK engager multifunctional antibodies. We look forward to bringing our novel cancer therapeutics to clinical trials starting in 2021.

Mark Posno, PhD, Vice President Business Development of ProteoNic, added: ProteoNic has consistently demonstrated that 2G UNicpremium vector technology enables economically viable production of biologics, even for products which have been proven difficult to express using more conventional technology. We are looking forward to starting our collaboration with Cytovia Therapeutics, Inc and maximizing productivity of NK Engager multifunctional antibodies.

ABOUT CYTOVIA THERAPEUTICS, INC Cytovia Therapeutics Inc is an emerging biotechnology company that aims to accelerate patient access to transformational immunotherapies, addressing several of the most challenging unmet medical needs in cancer and severe acute infectious diseases. Cytovia focuses on Natural Killer (NK) cell biology and is leveraging multiple advanced patented technologies, including an induced pluripotent stem cell (iPSC) platform for CAR (Chimeric Antigen Receptors) NK cell therapy, next-generation precision gene-editing to enhance targeting of NK cells, and NK engager multi-functional antibodies. Our initial product portfolio focuses on both hematological malignancies such as multiple myeloma and solid tumors including hepatocellular carcinoma and glioblastoma. The company partners with the University of California San Francisco (UCSF), the New York Stem Cell Foundation (NYSCF), the Hebrew University of Jerusalem, Macromoltek and CytoImmune Therapeutics. Learn more atwww.cytoviatx.com

ABOUT PROTEONIC BV ProteoNic is a privately held company with offices in Leiden, the Netherlands and in the Boston area, USA. The company offers technology for the generation of cell lines with greatly improved biologics production characteristics. The company commercializes its proprietary 2G UNic technology through licensing and partnership arrangements. For more information, seewww.proteonic.nl.

For more information please contact:

Cytovia Therapeutics Sophie Badr Vice President, Corporate Affairs 1(929) 317 1565 sophie.badre@cytoviatx.com

ProteoNic BV Mark Posno, PhD Vice President Business Development T: +1 617 480 8016 posno@proteonic.nl

The rest is here:
Cytovia Therapeutics Licenses Productivity-Boosting Manufacturing Technology for Its NK Engager Multifunctional Antibodies From ProteoNic -...

Global Huntington’s Disease Treatment Market- Industry Analysis and Forecast (2019-2027)- By Drug Type, Treatment, End-Users, and Region. – Good…

By Gene Therapy Clinics

Theglobal Huntingtons disease treatment marketwas valued US$ 1.53 Bn in 2019 and is expected to reach 3.23 Bn by 2027, at a CAGR of 46.68% during a forecast period.

Market Introduction:

Huntingtons disease is a rare genetic condition that affects the brain and results in the degeneration of the nerve cells. It occurs between the age of 30 and 50 and worsens with time. The disorder usually becomes fatal after 20 years of its occurrence. The symptoms of the targeted disorder include depression, mood swings, amnesia, involuntary movement, and weight loss. It is associated with Parkinsons disease and Alzheimers as well as other health complications. Huntingtons disease can be diagnosed through CT scans and MRIs.

The report study has analyzed the revenue impact of COVID-19 pandemic on the sales revenue of market leaders, market followers, and disrupters in the report, and the same is reflected in our analysis.

Market Drivers and Restraints:

Growth and advancement in the treatment process and machinery used to treat such disease are the leading factors for market growth. On-going scientific research responsible for awareness about Huntingtons disease amongst the population is considered as one of the major factors driving the growth of Huntingtons disease therapeutics market. Medical needs across the globe are seeking the attention of scientists and researchers to develop a therapy for Huntingtons disease. Furthermore, high investment by the pharmaceutical companies involved in the R&D sector to develop innovative and curative drugs for the disease is fuelling the growth of the global HD treatment market as there is no proper treatment available. Besides, the presence of alternative therapies, including speech therapy, psychotherapy, and physiotherapy strongly contributed and increased the potential of the market growth for Huntingtons disease therapeutics.

However, due to the presence of stringent regulation and policies, the number of approved drugs is limited, hampering the availability of the drug in the market whereby, hindering the market growth in the coming years.

Huntingtons Disease Treatment Market Segment analysis:

Based on the drug type segment, tetrabenazine is expected to dominate the overall market demand in the coming forecast as it is the only drug approved by the US FDA for the treatment of chorea in Huntingtons disease. Tetrabenazine provides significant benefits in the treatment of chorea associated with HD. Health-care providers need to screen patients carefully before initiating treatment with this medication due to the adverse effects of tetrabenazine. In the future, additional long-term and comparative studies would be useful for further clarification of the role of tetrabenazine in the treatment of HD-associated chorea. According to IQVIA, US sales of tetrabenazine tablets 12.5 mg and 25 mg were ~$ 0.119 Bn in the year 2019, projected to show significant growth during the forecasted period.

REQUEST FOR FREE SAMPLE REPORT:https://www.maximizemarketresearch.com/request-sample/65831

Huntingtons Disease Treatment Market Regional Analysis:

Regionally, North America is expected to dominate Huntingtons disease treatment market, the US is the major contributor with a reported market share of ~ 65.59% in the base year and is estimated to show steady growth during the forecasted period. The on-going R&D activities and investment by pharmaceutical companies in the region are projected to run the innovation of highly effective and improved drugs for the treatment of Huntingtons disorder. Furthermore, advancement in technology and the presence of numerous vendors based on small and large sales are majorly participating to invest in this market will boost the market growth in the coming years.

On the other hand, Europe is expected to show substantial market growth owing to its economic stability. Europe is estimated to hold the second-largest share in the market owing to the growing aging population along with rising research and development activities aiming at Huntingtons disease in the region.

The objective of the report is to present a comprehensive analysis of the Global Huntingtons Disease Treatment Market including all the stakeholders of the industry. The past and current status of the industry with forecasted market size and trends are presented in the report with the analysis of complicated data in simple language. The report covers all the aspects of the industry with a dedicated study of key players that includes market leaders, followers, and new entrants. PORTER, SVOR, PESTEL analysis with the potential impact of micro-economic factors of the market have been presented in the report. External as well as internal factors that are supposed to affect the business positively or negatively have been analysed, which will give a clear futuristic view of the industry to the decision-makers.

Recent Advances in the Treatment of Huntingtons Disease: Targeting DNA and RNA:

Recent developments in gene therapy, including antisense oligonucleotides, small interfering RNAs, and gene editing are bringing new hope to the Huntingtons community. This step is expected to contribute to the market growth on another level in terms of value.

The report also helps in understanding Global Huntingtons Disease Treatment Market dynamics, structure by analysing the market segments and project the Global Huntingtons Disease Treatment Market size. Clear representation of competitive analysis of key players by Application, price, financial position, Product portfolio, growth strategies, and regional presence in the Global Huntingtons Disease Treatment Market make the report investors guide.

DO INQUIRY BEFORE PURCHASING REPORT HERE:https://www.maximizemarketresearch.com/inquiry-before-buying/65831

Scope of Huntingtons Disease Treatment Market

Global Huntingtons Disease Treatment Market, By Drug Type

Tetrabenazine Antidepressants Antipsychotic Drugs Tranquilizers Others Global Huntingtons Disease Treatment Market, By Treatment

Symptomatic therapy Disease-modifying therapy Global Huntingtons Disease Treatment Market, By End-Users

Hospital Clinics Online Pharmacies Retail Pharmacies Others Global Huntingtons Disease Treatment Market, By Region

North America Europe Asia Pacific Latin America Middle East & Africa Key Players Operating the Huntingtons Disease Treatment Market

Alnylam Pharmaceuticals Inc AmpliPhi Biosciences Corp Ceregene Inc Lundbeck Prana Biotechnology Limited Teva Pharmaceutical Industries Ltd Cortex Pharmaceuticals Inc Vertex Pharmaceuticals Incorporated Auspex Pharmaceuticals SOM Biotech GlaxoSmithKline Siena Biotech Raptor Pharmaceutical Pfizer Palobiofarma Omeros Ipsen Valeant Pharmaceuticals International Inc

MAJOR TOC OF THE REPORT

Chapter One: Huntingtons Disease Treatment Market Overview

Chapter Two: Manufacturers Profiles

Chapter Three: Global Huntingtons Disease Treatment Market Competition, by Players

Chapter Four: Global Huntingtons Disease Treatment Market Size by Regions

Chapter Five: North America Huntingtons Disease Treatment Revenue by Countries

Chapter Six: Europe Huntingtons Disease Treatment Revenue by Countries

Chapter Seven: Asia-Pacific Huntingtons Disease Treatment Revenue by Countries

Chapter Eight: South America Huntingtons Disease Treatment Revenue by Countries

Chapter Nine: Middle East and Africa Revenue Huntingtons Disease Treatment by Countries

Chapter Ten: Global Huntingtons Disease Treatment Market Segment by Type

Chapter Eleven: Global Huntingtons Disease Treatment Market Segment by Application

Chapter Twelve: Global Huntingtons Disease Treatment Market Size Forecast (2019-2026)

Browse Full Report with Facts and Figures of Huntingtons Disease Treatment Market Report at:https://www.maximizemarketresearch.com/market-report/global-huntingtons-disease-treatment-market/65831/

About Us:

Maximize Market Research provides B2B and B2C market research on 20,000 high growth emerging technologies & opportunities in Chemical, Healthcare, Pharmaceuticals, Electronics & Communications, Internet of Things, Food and Beverages, Aerospace and Defense and other manufacturing sectors.

Contact info:

Name: Vikas Godage

Organization: MAXIMIZE MARKET RESEARCH PVT. LTD.

Email: sales@maximizemarketresearch.com

Contact: +919607065656/ +919607195908

Website:www.maximizemarketresearch.com

View post:
Global Huntington's Disease Treatment Market- Industry Analysis and Forecast (2019-2027)- By Drug Type, Treatment, End-Users, and Region. - Good...

After years of protest, a top hospital ended intersex surgeries. For activists, it took a deep toll. – USA TODAY

By Gene Therapy Clinics

Kate Sosin, The 19th Published 8:35 p.m. ET Aug. 10, 2020 | Updated 3:12 p.m. ET Aug. 11, 2020

This story was published in partnership with The 19th, a nonprofit, nonpartisan newsroom reporting on gender, politics and policy.

Eugene Robinson recovered from his double mastectomy on a hospital porch in Durham, North Carolina. It was August 1956, and as a Black child in the Jim Crow South, Robinson wasnt allowed to heal next to White patients.

Sarah Robinson, Eugenes mother, brought a daughter to the hospital. She returned home with a son. It was his third of four surgeries. Two of his nine siblings had undergone similar operations, but his relatives never talked about the fact that androgen insensitivity syndrome, a genetic intersex condition, ran in the family.

Nearly 65 years later, Sean Saifa Wall, 41, sifts through Robinsons medical records, looking for answers about his uncles story that might shed light on his own. Wall, like Robinson, is intersex.

Sean Saifa Wall is a co-founder of the Intersex Justice Project, which has protested intersex surgeries at Lurie Children's Hospital of Chicago for years. Since the 1960s, medical convention has been that intersex variances should be "corrected," often through a combination of surgeries and hormone therapy starting from infancy or before a child can consent.(Photo: Sarah-Ji/Intersex Justice Project)

Intersex is an umbrella term for people with variations in sex characteristics that dont fit neatly in the binary of male or female. Some intersex people are born with varying reproductive anatomy or sex traits some develop them later in life.About 1.7 percentof people are born intersex, according to a 2000 report byDr. Anne Fausto-Sterling.

Since the 1960s, medical convention has been that intersex variations should be corrected, often through a combination of painful surgeries and hormone therapy starting from infancy or before a child can consent. But on July 28, the Ann and Robert H. Lurie Childrens Hospital of Chicago became the first hospital in the United States to suspend the operations. The news comes after a three-year campaign against the hospital led by Wall and Pidgeon Pagonis, co-founders of the Intersex Justice Project.

Activists have been protesting intersex surgeries since 1996, when a group demonstrated outside the American Academy of Pediatrics convention in Boston. Since then,the U.N. has condemned the surgeries,which remain legal in almost every country in the world,as irreversible and unnecessary procedures that can cause permanent infertility and lifelong pain, incontinence, loss of sexual sensation, and mental suffering.

Wall knows that pain intimately.

Wall came out as gay at age 14. Then, he came out as transgender. In both cases, his mom lost it, he said. She was like, Why do you want to wear mens clothes, mens underwear?

But Walls oldest aunt reminded his mom about his intersex uncle, now deceased. His aunt said, Do you not remember playing with Queen Esther as a child?

And my mom was like, Whos that? And shes like, 'Thats Gene.

Wall says the memory blew my moms mind for seven years she had a sister. Looking back, she did remember Esther.

Eight of his family members were intersex, Wall says. The more that Wall started to talk about himself, the more his family opened up about their own histories.

Up until the time he was 13, Walls mom resisted doctors insistence that he have surgery to remove undescended testes, he says. She saw his older intersex siblings suffer through their own operations and thought they were unnecessary.

They told my mom that the testes were cancerous, Wall said. So his mom agreed to the surgery. Wall never had cancer.

He had spent two years under the care of a doctor that he says studied him, asking him questions about whether or not hormones made him less gay. Still, it wasnt until college, while doing a Yahoo internet search, that Wall pieced together that he is intersex.

I was so angry, he said. I was like, Oh, this is not fair. Its not right.' I didnt talk about it for a while. I would tell people here and there, but I didnt talk about it publicly because I had so much shame.

I was so angry. ... I would tell people here and there, but I didnt talk about it publicly because I had so much shame.

When he was 25, he started taking testosterone, something he wanted to do as a trans person to confirm his gender. But he wasnt metabolizing the testosterone the way most people on the hormone do.

I think I felt really suicidal, he said, referring to people constantly misgendering him. But I knew that if I took my own life, that no one would ever know what happened to me, and no one would ever know my side of the story.

Thats when Wall decided to start organizing for intersex rights.

For 19 years, Lurie patient Pidgeon Pagonis also believed they had survived ovarian cancer. The surgeries and exams started before Pagonis could remember, at 6 months old. They had another operation when they were 3 or 4 years old, and another when they were 10.

Pidgeon Pagonis, co-founder of the Intersex Justice Project, at a protest in 2017.(Photo: Sarah-Ji/Intersex Justic Project)

Since I was like 11 they would always just lift my shirt off, touch my chest and then pull my pants down and look at my vulva area, Pagonis recalls. And then theyd ask me questions like, How are you? How are your grades?

Pagonis thought that because of the cancer, they would never be able to have a baby. In truth, Pagonis never had cancer. Years of intersex surgeries to make their body conform to the idea of the female sex had left them unable to feel most sexual sensation.

They spent 18 years in and out of Lurie for surgeries, hormones and exams. Doctors would ask Pagonis if they had questions. Pagonis wanted to know why they were experiencing puberty differently than other kids.

I didnt know I had a vaginoplasty, and I didnt know I was intersex, Pagonis said. I did not know I had a castration, and I did not know I had a clitorectomy at that point. I thought I survived cancer.

Pagonis attended college practically in the shadow of the hospital at DePaul University, watching doctors come and go as they studied for finals. It wasnt until they learned about intersex issues at DePaul that they realized that all those visits to Lurie hadnt been about cancer at all.

I just thought these were my doctors that I had to go to because I had cancer when I was a kid, Pagonis said. And also, I was so unlucky that I had this urethra problem.

No other major U.S. hospital has ever stated that they dont perform intersex surgeries, so Lurie was far from the only institution performing such procedures. However, Lurie has enjoyed a sterling reputation among LGBTQ+ people since 2013, when it opened one of the first pediatric gender clinics in the nation under the leadership of Dr. Robert Garofalo, a nationally renowned expert in transgender health. Under Garofalos leadership in the Gender & Sex Development Program, Lurie became thefirst hospital in the United Statesto adopt a trans-inclusive policy for its young patients.

That prestige made Lurie a prime target for a campaign to end intersex surgeries. Intersex activists have long pointed to a disconnect between the gender-affirming care for trans and non-binary youth at the hospital and surgeries done on intersex children without their knowledge or consent.

The truth of the matter is they are very distinct and separate populations in many ways, said Garofalo. But there are areas where there are some overlaps.

And those cast a pall on the gender clinic as calls to end the surgeries overwhelmed its social media channels.

The Intersex Justice Project Pagonis and Walls organization of intersex activists of color led its first protests against Lurie in 2017 and again in 2018, when the Androgen Insensitivity Syndrome-Differences of Sex Development Support Group held its conference in Chicago. About 70 people showed up to protest outside Lurie. Since that time, Lurie has been the target of a relentless campaign to end the surgeries, and protests outside the hospital have only grown.

In July, Pose star Indya Moore excoriated the hospital for using their image to promote LGBTQ+ inclusion.

You cannot stand W/ trans ppl & step ON intersex ppl! Moorewrote on Twitter. The tweet set off a firestorm of bad press for the hospital as an old petition against the surgeries at Lurie racked up 45,000 signatures.

Garofalo said the hospital has long been revising its polices on intersex care, but it had never apologized for the harm those surgeries had caused.

I mean, the truth of the matter is that it has been uncomfortable for me at times, conceded Garofalo, who does not oversee intersex care at the hospital.

On July 28, the same day the hospital announced it was suspending the surgeries, the hospital apologized.

We empathize with intersex individuals who were harmed by the treatment that they received according to the historic standard of care, and we apologize and are truly sorry, the hospitalstatedin a letter signed by President and CEO Dr. Thomas Shanley. When it comes to surgery, we are committed to reexamining our approach.

Intersex is an umbrella term for people with variations in sex characteristics that dont fit neatly in the binary of male or female. About 1.7 percentof people are born intersex, according to a 2000 report byDr. Anne Fausto-Sterling.(Photo: Oleksii Liskonih, Getty Images/iStockphoto)

A number of staffers within Lurie pushed for an end to the surgeries, most notably transgender research coordinator Dr. Ellie Kim, who publicly criticized the practice.

I really owe Ellie a debt of gratitude for really stepping forward and not being shy about her thoughts on the matter, Garofalo said. And to that extent, Im really proud to be where Im at.

Luries end to intersex surgeries marks a watershed moment for intersex rights. Lurieis rankedamong the top pediatric hospitals in the nation, and intersex rights activists hope that other hospitals follow suit.

But for advocates like Wall, the campaign has also taken a deep toll. Pagonis and Wall garnered support and educated the public by sharing intimate personal stories. Its largely considered disrespectful for reporters to ask transgender people about their surgeries or genitalia. Intersex activists dont have that luxury yet, says Hans Lindahl, director of communications for youth intersex organization InterAct.

Something that we say a lot is that we have not yet had our Laverne Cox moment, said Lindahl. Were still so under the purview of being medicalized that I think theres a pressure that we almost have to tell these stories at this point in our movement in order to get people to listen.

For Pagonis and Wall, that has meant revealing details about their own traumas, sexual experiences, anatomy and family histories.

And largely lost in this moment is the history of intersex surgery itself. Intersex operations were born out of gynecology, a practice developed byJames Marion Sims, who performed brutal experiments on enslaved Black women without anesthesia. Although intersex surgeries were popularized in the 1960s, doctors had been doing them for years before, as Walls family history shows.

Wall says his family was already harassed as a Black family in the segregated South. But a Black family with three kids whose sex characteristics varied meant they were tormented endlessly.

So for me, my intersex story comes out of this legacy thats rooted in the South, thats rooted in North Carolina, Wall said. By the time this intersex variation appeared in my family, there was knowledge and awareness of it, but people didnt talk about it, because there was shame and stigma and secrecy.

Read or Share this story: https://www.usatoday.com/story/news/politics/2020/08/10/activists-against-intersex-surgeries-mark-lurie-win-heavy-cost/3320963001/

See the original post here:
After years of protest, a top hospital ended intersex surgeries. For activists, it took a deep toll. - USA TODAY

Global Bleeding Disorders Treatment Market- Industry Analysis and forecast 2019 2027: By Indication, Product Type, and Region. – Good Night, Good…

By Gene Therapy Clinics

Global Bleeding Disorders Treatment Marketsize was valued at US$ XX Bn. In 2019 and the total revenue is expected to grow at CAGR of 8.1% from 2020 to 2027, reaching nearly US$ XX Bn.

The report study has analyzed the revenue impact of COVID -19 pandemic on the sales revenue of Market leaders, Market followers, and Market disrupters in the report, and the same is reflected in our analysis.

Definition:

Bleeding disorders are a group of disorders in which the human body is inefficient to clot the blood. This is either hereditary or deficiency of blood clotting factors in blood called platelets. Bleeding disorder treatments help these patients with the formulation of platelets through medications, replacement therapy, and taking some precautions on their part to avoid the risk of bleeding.

REQUEST FOR FREE SAMPLE REPORT:https://www.maximizemarketresearch.com/request-sample/65796

Market Dynamics:

In 2019, the Bleeding disorders treatment market was valued at approximately US$ 9,687.11 million and is expected to grow further. Significant factors for the growth of this market are increased patient population, investment in R&D for the availability of advanced molecular drug formulas, the focus of the big companies in the development of recombinant products for efficient treatment. But this growth will be hindered by the exorbitant cost of treatment and limited reimbursement policies. In December 2018, the FDA approved emicizumab-kxwh as prophylaxis for patients with hemophilia A with or without factor VIII (FVIII) inhibitors. This drug was first approved in 2017 for patients with hemophilia A with FVIII inhibitors.

Market Segmentation:

Among the several types of bleeding disorders, Hemophilia A and Von Willebrand Disease are the most commonly seen in the patient-population. The former is a rare disorder mostly affecting the males while the latter in inherited and is high among the Americans. By the type of drugs used for treatment, Plasma-derived Coagulation products and Recombinant Coagulation products are largely used for treatment. In the 1950s, the plasma-derived products were widely used but it faced adversity due to the spread of HIV and the Hepatitis virus in the 1980s through plasma transfusion. Post-1980s, the recombinant products were used and still these are going through a phase of development.

Region-wise Analysis:

The Bleeding disorders treatment market is dominant in North America, valued at US$ 3.57 bn. in 2019, and will continue with growth since about 1% of the US population is affected by bleeding disorders due to iron deficiency and they are availing the prophylaxis treatment for it. This is complemented with the high presence of major companies in North America. This is followed by Europe, where the growth in the bleeding disorder treatment market is due to high R&D investment facilitating technological advancement and innovations.

Competitive Landscape:

The competitive landscape section in the Bleeding Disorders Treatment market offers a deep dive into the profiles of the leading players operating in the global market landscape. It offers captivating insights on the key developments, differential strategies, and other crucial aspects about the companies having a stronghold in the Bleeding Disorders Treatment market. Gene therapy trials are conducted in the Boston Childrens Hospital to treat Hemophilia in children.

The objective of the report is to present a comprehensive analysis of the Global Bleeding Disorders Treatment Market including all the stakeholders of the industry. The past and current status of the industry with the forecasted market size and trends are presented in the report with the analysis of complicated data in simple language. The report covers all the aspects of the industry with a dedicated study of key players that includes market leaders, followers, and new entrants. PORTER, SVOR, PESTEL analysis with the potential impact of micro-economic factors of the Market has been presented in the report. External as well as internal factors that are supposed to affect the business positively or negatively have been analyzed, which will give a clear futuristic view of the industry to the decision-makers. The report also helps in understanding Global Bleeding Disorders Treatment Market dynamics, structure by analyzing the Market segments and projects the Global Bleeding Disorders Treatment Market size. Clear representation of competitive analysis of key players by Application, price, financial position, Product portfolio, growth strategies, and regional presence in the Global Bleeding Disorders Treatment Market make the report investors guide.

DO INQUIRY BEFORE PURCHASING REPORT HERE:https://www.maximizemarketresearch.com/inquiry-before-buying/65796

Scope of the Global Bleeding Disorders Treatment Market

Global Bleeding Disorders Treatment Market, by Disease Type

Hemophilia A Hemophilia B Von Willebrand Disease Liver Disease Others Global Bleeding Disorders Treatment Market, Drug Type

Plasma-derived Coagulation Factor Concentrates o Factor VIII o Factor IX o Factor for Von Willebrand Disease o Activated Prothrombin Complex Concentrate Recombinant Coagulation Factor Concentrates o Factor VIII o Factor for Von Willebrand Disease o Factor IX Desmopressin Antifibrinolytics Fibrin Sealants Others Global Bleeding Disorders Treatment Market, By End User

Hospitals Clinics Academic Institutions Global Bleeding Disorders Treatment Market, By Region

Asia Pacific North America Europe Latin America Middle East Africa Key players operating in Global Bleeding Disorders Treatment Market

Shire Bayer AG Biogen Inc. CSL Behring Novo Nordisk Pfizer Inc. Grifols Baxter International Inc. Alnylam Pharmaceuticals, Inc. Xenetic Biosciences, Inc. Bristol-Myers Squibb Company Octapharma Sanofi Amgen, Inc. Bioverativ Janssen Global Services, LLC Cangene Corporation BDI Pharma Sun Pharmaceutical Industries Ltd. Ferring Pharmaceuticals Roche Pharmaceuticals

MAJOR TOC OF THE REPORT

Chapter One: Bleeding Disorders Treatment Market Overview

Chapter Two: Manufacturers Profiles

Chapter Three: Global Bleeding Disorders Treatment Market Competition, by Players

Chapter Four: Global Bleeding Disorders Treatment Market Size by Regions

Chapter Five: North America Bleeding Disorders Treatment Revenue by Countries

Chapter Six: Europe Bleeding Disorders Treatment Revenue by Countries

Chapter Seven: Asia-Pacific Bleeding Disorders Treatment Revenue by Countries

Chapter Eight: South America Bleeding Disorders Treatment Revenue by Countries

Chapter Nine: Middle East and Africa Revenue Bleeding Disorders Treatment by Countries

Chapter Ten: Global Bleeding Disorders Treatment Market Segment by Type

Chapter Eleven: Global Bleeding Disorders Treatment Market Segment by Application

Chapter Twelve: Global Bleeding Disorders Treatment Market Size Forecast (2019-2026)

Browse Full Report with Facts and Figures of Bleeding Disorders Treatment Market Report at:https://www.maximizemarketresearch.com/market-report/global-bleeding-disorders-treatment-market/65796/

About Us:

Maximize Market Research provides B2B and B2C market research on 20,000 high growth emerging technologies & opportunities in Chemical, Healthcare, Pharmaceuticals, Electronics & Communications, Internet of Things, Food and Beverages, Aerospace and Defense and other manufacturing sectors.

Contact info:

Name: Vikas Godage

Organization: MAXIMIZE MARKET RESEARCH PVT. LTD.

Email: sales@maximizemarketresearch.com

Contact: +919607065656/ +919607195908

Website:www.maximizemarketresearch.com

Link:
Global Bleeding Disorders Treatment Market- Industry Analysis and forecast 2019 2027: By Indication, Product Type, and Region. - Good Night, Good...

How MC Hammer And Other Performing Artists Are Sharing Their Love Of Science – Forbes

By Stem Cell Medical Center

If you've been keeping tabs on MC Hammer lately, you may have noticed that he spent the last few weeks enthusiastically talking about science on Twitter. He tweeted about a gene found in neurons, about worm RNA, about slime molds, and much more.

MC Hammer has been sharing his love of science with his Twitter followers in the last few weeks. ... [+] (Pictured here during a Capitol Music Group event on August 8, 2018 in LA. Photo by Rich Polk/Getty Images for Capitol Music Group)

This isn't unprecedented. It's not unusual for MC Hammer to talk about science (he was tweeting about laser-controlled fly brains back in 2014) and it's not unusual for performing artists in general to be vocal supporters of science.

Over the last few years, several other musicians have publicly shared their fascination with various fields of science. A few years ago, singer Charlotte Church revealed that she loves physics. meanwhile, Ben Folds and Rosanne Cash both developed an interest in neuroscience. Folds has spoken with neuroscientist Daniel Levitin about the science behind music, and Cash collaborated with neuroscientist-led band The Amygdaloids on a song. The Wu-Tang Clan's GZA has been focusing on science-themed rap the past decade, creating an as-yet unreleased science album. Bjrk also released a science-inspired album in 2011.

And then there are the scientists with high-profile music careers. Long before he became a TV science presenter and physicist, Brian Cox was keyboard player in '90s band D:Ream. Queen guitarist Brian May quit his astrophysics PhD when the band became too popular to manage both careers, but he picked it back up a few decades later. He now occasionally works on science communication projects with NASA and others. The Offspring's Dexter Holland also paused a PhD during the height of his band's success and returned to USC to finish his PhD in 2017. His thesis on the molecular biology of HIV on got a mention in Rolling Stone.

Some performing artists use their platform to raise attention and money for specific causes. Country singer Willie Nelson is interested in stem cell therapy and has supported the field by raising funds for the University of Texas' Southwestern Medical Center. Meanwhile, actors Michael J Fox and Leonardo DiCaprio both run foundations that support scientific research. Fox launched his foundation in 2000 to provide funding and resources for Parkinson's Disease after he was diagnosed with the condition himself. DiCaprios foundation supports environmental research, and has partly funded a range of research projects, such as a study on kelp forests or research on wildland fires.

The list goes on. For every celebrity that gets unwarranted attention for peddling unproven treatments or gimmicks, you'll find several others being the voice of reason and using their platform to support science. And that public support is something that researchers very much appreciate.

Scientists often have the intention to communicate their work widely, but the constrant struggle to survive beyond their current grant pressures them to focus on getting the research done and published in specialized journals, often without finding the time to share that work with the wider world. However, people are trying to change this through new science communication methods. The field of science communication studies how research is shared and looks for ways to connect people with science. Here, too, we find a celebrity. After presenting the PBS show Scientific American Frontiers, actor Alan Alda founded the Alan Alda Center For Science Communication, which offers advice and training for researchers to help them share their story with others.

In a 2016 interview with the Australian National University, Alda emphasizes that it's important to show the people behind the research. "I think when we see scientists as human beings, the door is open for us a little bit, we can go into their lives. Theyre not the white-coated gurus on the mountaintop."

Showing scientists as human beings is exactly what MC Hammer has been doing with his platform. This week, he has been supporting the #BlackInChem initiative, amplifying the profiles of black chemists and showing his followers some of the people behind the research.

Scientists on Twitter have been understandably excited when MC Hammer retweets them. Not just because of the brief brush with fame, but because researchers are always trying to reach new people with their work.

It can be hard to share science with people beyond the usual science fans. People have to want to attend a science festival, purposely buy a popular science magazine, or deliberately tune in to a science show. Online, our algorithms keep feeding us the same topics we always look at. But by using their platform to share science news and scientist profiles, high-profile performing artists like MC Hammer can break through that bubble and give their audience a glimpse into a world that they might otherwise not seek out themselves.

Link:
How MC Hammer And Other Performing Artists Are Sharing Their Love Of Science - Forbes

Cellect Biotechnology Reports Second Quarter Financial and Operating Results; First Half 2020 Strategic Developments Create Long-Term Revenue…

By Stem Cell Medicine

TEL AVIV, Israel, Aug. 12, 2020 /PRNewswire/ -- Cellect Biotechnology Ltd. (NASDAQ: APOP), a developer of innovative technology which enables the functional selection of stem cells, today reported financial and operating results for the second quarter ended June 30, 2020. The Company's six-month progress includes the development of several strategic initiatives, including growth-oriented opportunities in pain management and COVID-19 related therapeutics.

"Despite the COVID-19 pandemic business disruptions and the near-term delays to completing and commencing our clinical programs in Israel and the U.S., respectively, we acted swiftly over the past few months to leverage our sought-after technology to create several long-term business initiatives to enhance our value," commented Dr. Shai Yarkoni, Chief Executive Officer. "In addition to pursuing a potential merger with a global leader in the high growth medical-grade cannabis market, which is being delayed due to COVID-19, we have either initiated or are contemplating other business development activities that will greatly benefit from our innovation, technology and know-how. I believe each of these opportunities represents meaningful catalysts for Cellect in multi-billion-dollar markets, subject to resolution of the COVID-19 pandemic and return to normal course of business."

Notwithstanding the continued delays due to COVID-19, the Company remains focused on the following operational and clinical objectives:

The Company's cash and cash equivalents totaled $7 million as of June 30, 2020, which includes the approximately $1.5 million (gross before expenses)resulting from several investors exercising certain warrants that were issued in February 2019.

SecondQuarter 2020 Financial Results:

*For the convenience of the reader, the amounts above have been translated from NIS into U.S. dollars, at the representative rate of exchange on June 30, 2020 (U.S. $1 = NIS 3.466).

About Cellect Biotechnology Ltd.

Cellect Biotechnology (APOP) has developed a breakthrough technology, for the selection of stem cells from any given tissue, that aims to improve a variety of stem cell-based therapies.

The Company's technology is expected to provide researchers, clinical community and pharma companies with the tools to rapidly isolate stem cells in quantity and quality allowing stem cell-based treatments and procedures in a wide variety of applications in regenerative medicine. The Company's current clinical trial is aimed at bone marrow transplantations in cancer treatment.

Forward Looking Statements

This press release contains forward-looking statements about the Company's expectations, beliefs and intentions. Forward-looking statements can be identified by the use of forward-looking words such as "believe", "expect", "intend", "plan", "may", "should", "could", "might", "seek", "target", "will", "project", "forecast", "continue" or "anticipate" or their negatives or variations of these words or other comparable words or by the fact that these statements do not relate strictly to historical matters. For example, forward-looking statements are used in this press release when we discuss Cellect's expectations regarding timing of the commencement of its planned U.S. clinical trial and its plan to reduce operating costs. These forward-looking statements and their implications are based on the current expectations of the management of the Company only and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. In addition, historical results or conclusions from scientific research and clinical studies do not guarantee that future results would suggest similar conclusions or that historical results referred to herein would be interpreted similarly in light of additional research or otherwise. The following factors, among others, could cause actual results to differ materially from those described in the forward-looking statements: the Company's history of losses and needs for additional capital to fund its operations and its inability to obtain additional capital on acceptable terms, or at all; the Company's ability to continue as a going concern; uncertainties of cash flows and inability to meet working capital needs; the Company's ability to obtain regulatory approvals; the Company's ability to obtain favorable pre-clinical and clinical trial results; the Company's technology may not be validated and its methods may not be accepted by the scientific community; difficulties enrolling patients in the Company's clinical trials; the ability to timely source adequate supply of FasL; risks resulting from unforeseen side effects; the Company's ability to establish and maintain strategic partnerships and other corporate collaborations; the scope of protection the Company is able to establish and maintain for intellectual property rights and its ability to operate its business without infringing the intellectual property rights of others; competitive companies, technologies and the Company's industry; unforeseen scientific difficulties may develop with the Company's technology; the Company's ability to retain or attract key employees whose knowledge is essential to the development of its products; and the Company's ability to pursue any strategic transaction or that any transaction, if pursued, will be completed. Any forward-looking statement in this press release speaks only as of the date of this press release. The Company undertakes no obligation to publicly update or review any forward-looking statement, whether as a result of new information, future developments or otherwise, except as may be required by any applicable securities laws. More detailed information about the risks and uncertainties affecting the Company is contained under the heading "Risk Factors" in Cellect Biotechnology Ltd.'s Annual Report on Form 20-F for the fiscal year ended December 31, 2019 filed with the U.S. Securities and Exchange Commission, or SEC, which is available on the SEC's website, http://www.sec.gov, and in the Company's periodic filings with the SEC.

Cellect Biotechnology Ltd.

Consolidated Statement of Operation

Convenience

translation

Six months

ended

Six months ended

Three months ended

June 30,

June 30,

June 30,

2020

2020

2019

2020

2019

Unaudited

Unaudited

U.S. dollars

NIS

(In thousands, except share and per

share data)

Research and development expenses

837

2,901

7,086

1,364

3,564

General and administrative expenses

1,356

4,703

5,064

2,116

2,709

Operating loss

2,193

7,604

12,150

3,480

6,273

Financial expenses (income) due to warrants exercisable into shares

1,098

3,807

(7,111)

4,697

(5,919)

Other financial expenses (income), net

(15)

(55)

880

627

462

Total comprehensive loss

3,276

11,356

5,919

8,804

816

Loss per share:

Basic and diluted loss per share

0.010

0.034

0.029

0.024

0.004

Weighted average number of shares outstanding used to compute basic and diluted loss per share

338,182,275

338,182,275

200,942,871

365,428,101

224,087,799

Cellect Biotechnology Ltd.

Consolidated Balance Sheet Data

Convenience

translation

June 30,

June 30,

December 31,

2020

2020

2019

Unaudited

Unaudited

Go here to read the rest:
Cellect Biotechnology Reports Second Quarter Financial and Operating Results; First Half 2020 Strategic Developments Create Long-Term Revenue...

California Propositions on the 2020 Ballot – Fullerton Observer

By Stem Cell Medicine

Local News

In addition to voting for candidates, California voters will be asked to vote on several ballot measures this November. Heres a breakdown of each Proposition on the ballot.

Prop. 14: Stem Cell Research Funding

Would issue $5.5 billion in bonds for the California Institute for Regenerative Medicine (CIRM), which was created to fund stem cell research.

Support has raised $6.58 million, with $4.63 million from Robert N. Klein II, a real estate investor and stem-cell research advocate.

There were no committees registered to oppose the ballot initiative.

For more information about the measure, click HERE. For the latest financial contributions, click HERE.

Prop. 15: Property Tax Increase on Commercial and Industrial Properties for Education and Local Government Funding

Would allow commercial and industrial properties (with some exceptions) to be taxed based on their market value, as opposed to their assessed value. Residential properties would not be affected. The State fiscal analyst estimated that the ballot initiative would generate between $8 billion and $12.5 billion in revenue per year. Revenue would be distributed mostly to local governments, school districts, and community colleges.

Support has raised $21 million, including $6 million from the California Teachers Association Issues PAC.

Opposition has raised $5.5 million, including $266,490 from the California Business Roundtable Issues PAC.

For more information about the measure, click HERE. For the latest financial contributions, click HERE.

Prop. 16: Ending the Ban on Affirmative Action

Would remove the ban on affirmative action involving race-based or sex-based preferences from the California Constitution by repealing Proposition 209 (1996). State and local governments, public universities, and other public entities wouldwithin the limits of federal lawbe allowed to develop and use affirmative action programs that grant preferences based on race, sex, color, ethnicity, and national origin in public employment, public education, and public contracting.

Support has raised $3.14 million. M. Quinn Delaney is the largest donor, contributing $1,500,000.

Opposition has raised $105,678, including $50,000 from Students for Fair Admissions, Inc.

For more information about the measure, click HERE. For the latest financial contributions, click HERE.

Prop. 17: Restoring the Right to Vote to People on Parole

Would allow people on parole for felony convictions to vote in California. Currently, the California Constitution disqualifies people with felonies from voting until their imprisonment and parole are completed.

Campaign finance data has not been reported.

For more information about the measure, click HERE. For the latest financial contributions, click HERE.

Prop. 18: Letting (some) 17-year-olds Vote

Would allow 17-year-olds who will be 18 at the time of the next general election to vote in primary elections and special elections.

Campaign finance data has not been reported.

For more information about the measure, click HERE. For the latest financial contributions, click HERE.

Prop. 19: Property Tax Breaks

Would allow homeowners who are over 55, disabled, or victims of natural disaster to take a portion of their property tax base with them when they sell their home and buy a new one. It would also limit the ability of new homeowners who inherit properties to keep their parents or grandparents low property tax payments. Most of the additional money raised would go into a State fire response fund.

Support has raised $19.15 million with $15.70 million from The California Association of Realtors Issues Mobilization PAC.

For more information about the measure, click HERE. For the latest financial contributions, click HERE.

Prop. 20: Criminal Sentencing, Parole, and DNA Collection Initiative

Would amend several criminal sentencing and supervision laws that were passed between 2011 and 2016.

Would allow prosecutors to charge repeat or organized petty theft as a felony, require probation officers to seek tougher penalties for those who violate the term of their parole 3 times, and exclude those who have been convicted of domestic violence and certain nonviolent crimes from early parole consideration.

Support has raised $1.6 million with $50,000 from San Bernadino County Sheriffs Employees Benefit Association Committee.

Opposition has raised $2.1 million with major funding from the Schusterman Foundation, the Heising-Simons Action Fund, and Patty Quillin.

For more information about the measure, click HERE. For the latest financial contributions, click HERE.

Prop. 21: Local Rent Control Initiative

Would allow cities to introduce new rent control laws, or expand existing ones.

Support has raised $16.68 million, with 99.8% from the AIDS Healthcare Foundation.

Opposition has raised $16.25 million, including $4.70 million from Essex Property Trust, $117,000 from California Rental Housing Association, and other property owner groups.

For more information about the measure, click HERE. For the latest financial contributions, click HERE.

Prop. 22: Self-employment for ride-hail and other app-drivers

Would consider app-based drivers to be independent contractors and not employees or agents. Therefore, the ballot measure would override Assembly Bill 5 (AB 5), signed in September 2019, on the question of whether app-based drivers are employees or independent contractors.

Support has raised $111 million, including $30 million from Lyft, $30 million from Uber, and $30 million from DoorDash.

Opposition has raised $866,591, with the Transport Workers Union of America providing $500,000.

For more information about the measure, click HERE. For the latest financial contributions, click HERE.

Prop. 23: Dialysis Clinic Requirements

Would require chronic dialysis clinics to have a minimum of one licensed physician present at the clinic and to report data on dialysis-related infections to the State and federal health officials.

The ballot measure would also state that a chronic dialysis clinic cannot discriminate with respect to offering or providing care nor refuse to offer or to provide care, on the basis of who is responsible for paying for a patients treatment.

Support has raised $6 million from a healthcare workers union.

Opposition has raised $2 million, with $1 million from DaVita, Inc. and $1 million from Fresenius Medical Care (dialysis clinics).

For more information about the measure, click HERE. For the latest financial contributions, click HERE.

Prop. 24: Consumer Privacy Protections

Would strengthen Californias consumer privacy law and establish a California Privacy Protection Agency.

Support has raised $4.76 million with most funding from developer Alastair Mactaggart.

No opposition funding has been reported.

For more information about the measure, click HERE. For the latest financial contributions, click HERE.

Prop. 25: Replace Cash Bail with Risk Assessments

Would end the States cash bail system and give judges the right to determine whether someone who is arrested should be kept behind bars based on the risk they are deemed to pose to themselves or others.

Support has raised $1.36 million. Action Now Initiative was the largest donor, contributing $500,000.

Opposition has raised $4.24 million, including $921,633. from Triton Management Services, LLC and the bail bond industry.

For more information about the measure, click HERE. For the latest financial contributions, click HERE.

Visit the California Secretary of State ballot measures page HERE.

Orange County voters will have three options for returning their ballots.

Protect local journalism please subscribe to the print edition of the Fullerton Observer. Our online edition is free, but we depend on print subscriptions from readers. Annual subscription is only $35/year.It only takes a minute Click Here To Subscribe. Thank you for your support for the Fullerton Observer. Click here to view a copy of the print edition.

Continued here:
California Propositions on the 2020 Ballot - Fullerton Observer

Gore partners with San Diego company on cell delivery system with potential to treat Type 1 diabetes – delawarebusinessnow.com

By Stem Cell Medicine

ViaCyte, Inc. and Newark-based W. L. Gore & Associates, Inc. announced the two companies have signed an agreement covering the next phase of their collaboration focused on the development of ViaCytes Encaptra Cell Delivery System that uses Gore material technologies.

The technology is designed to produce insulin for patients with Type I diabetes, formerly known as juvenile diabetes.

The Encaptra System could be a transformative therapy for patients with type 1 diabetes, the companies noted.

Tapping into Gores world-class materials science and medical device expertise, new membrane technology was developed that appears to allow successful engraftment and beta cell proliferation while minimizing the host foreign body response, said Paul Laikind, CEO of ViaCyte. This agreement is an important next step on our path towards a commercial product as well as a template for future agreements for additional work ViaCyte and Gore may do together on cell delivery technology.

Our collaboration with ViaCyte has been very productive in enabling the clinical advancement of the PEC-Encap product candidate with proprietary Gore materials technology, said Erin Hutchinson, business leader, Gore PharmBIO Cell Encapsulation Products. We are delighted to further strengthen our collaboration on the path to the delivery of a potentially functional curative product for those currently suffering with type 1 diabetes and help pioneer the new field of cell replacement therapy.

ViaCyte is the only company with stem cell-derived islet replacement candidates undergoing clinical testing and the only group to show that the implanted cells are capable of producing insulin in people with type 1 diabetes.

The Companys promising candidates have the potential to deliver a functional cure for people with type 1 diabetes and could be an advancement for people with insulin-requiring type 2 diabetes.

Under the terms of the agreement, Gore will manufacture and supply a proprietary membrane and the device component for use with ViaCytes PEC-Encap product candidate.

The novel Gore membrane has been evaluated in preclinical studies. Gore will continue to collaborate with ViaCyte to optimize the device design and implant techniques in support of human clinical trials.

Early human clinical trials of PEC-Encap with the new membrane are underway and preliminary histological results are encouraging. Should the membrane prove successful in the ongoing trial, Gore will assume the responsibility for manufacturing the Encaptra System incorporating the novel membrane technology for late stage clinical development and commercial use.

ViaCyte has shown that once implanted and successfully engrafted PEC-01 cells mature into beta cells that secrete insulin in a regulated manner to control blood glucose levels. The Encaptra System serves to protect the PEC-01 cells from the host immune system thus eliminating the need for immune suppression drugs commonly used with other transplants.

A critical enabling component of the Encaptra System that contains and protects the cells is a specifically designed semi-permeable membrane that encapsulates the cells but allows for diffusion of oxygen and nutrients into the device and insulin and other hormones out of the device and into the circulation.

The Encaptra System membrane is composed of an expanded PTFE composite, similar to materials that are used in Gores implantable medical products..

Gore and ViaCyte began a collaboration in 2017.

ViaCyte is funded in part by the California Institute for Regenerative Medicine (CIRM) and JDRF. ViaCyte is headquartered in San Diego.

Continue reading here:
Gore partners with San Diego company on cell delivery system with potential to treat Type 1 diabetes - delawarebusinessnow.com

FibroGenesis Reports Breakthrough in Prevention of COVID-19 Blood Clotting Laboratory Studies Suggest PneumoBlast COVID-19 Cell Therapy Reduces…

By Stem Cell Medicine

HOUSTON, Aug. 12, 2020 (GLOBE NEWSWIRE) FibroGenesis, a clinical stage company developing fibroblast based therapeutic solutions for unmet medical needs, announced today new data supporting utilization of its PneumoBlast product in treatment of COVID-19. Laboratory experiments comprised of admixing PneumoBlast with activated monocyte or endothelial cells demonstrated significant inhibition of tissue factor expression. Tissue factor is the key molecule inducing blood clotting in COVID-19 patients. Monocytes are cells which normally protect the body against pathogens. In the case of COVID-19, monocytes enter the lungs and cause coagulation. Endothelial cells are cells which make up the inside of the blood vessel and regulate substance flow between the bloodstream and surrounding tissues.

It was observed that treatment of activated monocytes with PneumoBlast resulted in a 77% reduction of tissue factor expression as compared to untreated monocytes (p,lt; 0.001). Mixture of mesenchymal stem cells with activated monocytes resulted in a 13% inhibition of tissue factor expression (p= 0.01). Furthermore, in activated endothelial cells, PneumoBlast decreased expression of tissue factor by 80% (p,lt; 0.001), whereas mesenchymal stem cells resulted in a 30% (p= 0.01) reduction.

It is believed that a significant cause of morbidity and mortality in COVID-19 occurs because of unrestrained blood clotting. Studies have shown the high propensity for clotting in COVID-19 patients is associated with inflammation. The Company previously demonstrated PneumoBlast reduces proteins necessary for inflammation, such as TNF-alpha. The current study shows PneumoBlast can also work downstream of inflammation and directly suppress the clotting cascade.

This data is truly stunning, said Tom Ichim, Ph.D., Chief Scientific Officer of FibroGenesis. Currently one of the major obstacles to successful treatment of COVID-19 is the unusually high level of unregulated coagulation, which in many cases is not resolved by standard anticoagulants. The ability of PneumoBlast cells to reduce blood clotting potential in both monocytic and endothelial cells speaks volumes about the multifactorial mechanisms by which we believe our product will work on COVID-19.

We are thankful for our team of clinical collaborators and scientists who are exploring and identifying novel mechanisms by which PneumoBlast appears to be effective against COVID-19, commented Pete OHeeron, President and CEO of FibroGenesis. We are the first cell therapy company to address the issue of coagulation in COVID-19. We see this, as another indication of the superiority of fibroblasts compared to stem cells.

About FibroGenesis

Based in Houston, Texas, FibroGenesis, is a regenerative medicine company developing an innovative solution for chronic disease treatment using human dermal fibroblasts. Currently, FibroGenesis holds 235+ U.S. and international issued patents/patents pending across a variety of clinical pathways, including Disc Degeneration, Multiple Sclerosis, Parkinsons, Chronic Traumatic Encephalopathy, Cancer, Diabetes, Liver Failure, Colitis and Heart Failure. Funded entirely by angel investors, FibroGenesis represents the next generation of medical advancement in cell therapy.

Visit http://www.Fibro-Genesis.com.

Read this article:
FibroGenesis Reports Breakthrough in Prevention of COVID-19 Blood Clotting Laboratory Studies Suggest PneumoBlast COVID-19 Cell Therapy Reduces...

→←